Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Gene Biotherapeutics, Inc. | crxm-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2018
Taxus Cardium Pharmaceuticals Group, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-33635 |
27-0075787 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
|
|
|
|
|
11568 Sorrento Valley Rd., Suite 14 |
|
|
|
San Diego, California |
|
92121 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
||
|
Registrant’s telephone number, including area code: (858) 436-1000 |
||
|
|
||
|
(Former name or former address, if changed since last report.) |
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On January 8, 2018, Taxus Cardium Pharmaceuticals Group Inc. issued a press release announcing its plans to affect a name change from “Taxus Cardium Pharmaceuticals Group Inc.” to “Gene Biotherapeutics Inc.”
Item 9.01. Financial Statements and Exhibits.
|
Exhibit No. |
|
Description of Exhibit |
|
99.1 |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Taxus Cardium Pharmaceuticals Group, Inc. |
||
|
|
|
|
|
By: |
|
/s/ Christopher J. Reinhard |
|
|
|
Christopher J. Reinhard |
|
|
|
Chief Executive Officer |
Date: January 9, 2018